Chino Hills, CA, Aug. 09, 2018 (GLOBE NEWSWIRE) -- We are advised by SOHM, Inc. (PINKSHEETS: SHMN) that journalists and other readers should disregard the news release, "SOHM, Inc. Subsidiary Daiichi Sankyo Group Files Its Acute Myeloid Leukemia (AML) Treatment Quizartinib in the US; the FDA Awarded Breakthrough Status for The Drug," issued Thursday, August 9, 2018, over GlobeNewswire.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0009 USD | 0.00% | 0.00% | -35.71% |
1st Jan change | Capi. | |
---|---|---|
-35.71% | 0 | |
+63.05% | 856B | |
+39.42% | 631B | |
-4.78% | 359B | |
+17.52% | 325B | |
+8.43% | 297B | |
+14.19% | 244B | |
+5.81% | 234B | |
+16.77% | 226B | |
+14.63% | 177B |
- Stock Market
- Equities
- SHMN Stock
- News SOHM INC
- NOTICE TO DISREGARD - SOHM, Inc.